市场调查报告书
商品编码
1563124
止血和组织封闭剂的全球市场:依产品、材料、应用、最终用户和地区的预测(~2032年)Global Hemostasis and Tissue Sealing Agents Market Research Report Information by Product, By Material, By Application, By End-User, and Region Forecast till 2032 |
止血和组织封闭剂市场规模预计将从2023年的83.9亿美元,2024年的90.2亿美元,到2032年将成长到181.9亿美元,预测期内年复合成长率为 8.04%。道路交通事故和慢性血液疾病发病率上升、全球对微创手术的需求以及人口老化等因素推动市场扩张。
慢性血液疾病盛行率的增加是推动市场成长的因素。患有某些血液疾病(例如血友病和冯维勒布兰德病)的人凝血因子较低,更容易出血。对患有这些疾病的人进行手术和药物干预时可能需要使用止血剂,以促进血液凝固和控制出血。国际血栓与止血学会2022年最新版估计,全球每年约有1,000万例静脉血栓栓塞病例。据该组织表示,欧洲每年有 544,000 人死于深部静脉血栓(DVT)。
区域洞察
2023年北美药品市场占最大市占率。这是由于人口老化、慢性病的增加以及医疗技术的进步。该市场致力于改善患者治疗效果和减少术后併发症,已发展成为研发中心,并不断推出具有卓越疗效的新疗法。
由于有利的医疗政策和包括咨询在内的联合治疗,欧洲市场预计将占据第二大市场占有率。
估计2024年至2032年亚太市场将以最快的速度发展。这是由于经济快速扩张、中产阶级不断壮大以及都市化进程不断加速。该地区的人口成长推动对医疗保健、技术和消费品的需求。对基础设施、教育和技术的大力投资推动产业发展和创新。
本报告调查了全球止血剂和组织封闭剂市场,提供市场的定义和概述,市场成长的各种影响因素分析,市场规模推移和预测,各种区分、地区的细分,竞争环境,主要企业概况等彙整资料。
Global Hemostasis and Tissue Sealing Agents Market Research Report Information by Product (Topical Hemostat, Adhesive & Tissue Sealant), By Material (Chitosan-based Products, Mineral based Products), By Application (Trauma, General Surgery, Minimally Invasive Surgery, Gynecology Others), By End-User (Hospitals, Ambulatory Surgical Centers, Research Institutes), and Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032
In 2023, the market for hemostasis and tissue sealing agents was estimated to be worth USD 8.39 billion. The Hemostasis and Tissue Sealing Agents Market is expected to increase from USD 9.02 billion in 2024 to USD 18.19 billion by 2032, with a compound annual growth rate (CAGR) of 8.04% over the forecast period (2024-2032). Rising rates of traffic accidents and chronic blood problems, a global demand for minimally invasive procedures, and an aging population are driving market expansion.
The increasing prevalence of chronic blood diseases is another element driving market growth. Individuals with certain blood disorders, such as hemophilia or von Willebrand disease, are more likely to bleed because their clotting factors are compromised. Hemostasis drugs, which enhance blood clotting and limit bleeding, may be required in surgical procedures or medicinal interventions for people with these conditions. For example, the International Society on Thrombosis and Hemostasis' 2022 update estimates that approximately 10 million cases of venous thromboembolism occur globally each year. According to the same source, 544,000 persons in Europe die each year from Deep Vein Thrombosis (DVT).
Market Segment insights
Hemostasis and Tissue Sealing Agents Product-based market segmentation includes Topical Hemostat and adhesive & tissue sealant.
The market is segmented by material, which comprises chitosan-based products and mineral-based products.
The market is segmented by end user, which includes hospitals, ambulatory surgical centers, and research institutes.
Regional insights
The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. The North American Hemostasis and Tissue Sealing Agents market had the biggest market share in 2023. Because of the aging population, the rising prevalence of chronic diseases, and the ongoing advancement of medical technology. With a focus on improving patient outcomes and lowering postoperative complications, the market has evolved into a hub for research and development, resulting in the introduction of novel treatments with superior efficacy.
The European Hemostasis and Tissue Sealing Agents market is estimated to account for the second-largest market share due to favorable health policies and a tendency toward combining Hemostasis and Tissue Sealing Agents, including counseling. Furthermore, the German Hemostasis and Tissue Sealing Agents market was found to have the greatest market share, while the French Hemostasis and Tissue Sealing Agents market is predicted to be the fastest-growing market in the European area.
The Asia-Pacific Hemostasis and Tissue Sealing Agents market is estimated to develop at the quickest rate between 2024 and 2032. This is the result of rapid economic expansion, a growing middle class, and greater urbanization. The region's growing population fuels demand for healthcare, technology, and consumer products. Robust investments in infrastructure, education, and technology drive industrial development and innovation.
The Middle East, Africa, and Latin America are all part of the Rest of the World. The primary drivers driving the rise of Hemostasis and Tissue Sealing Agents in the Middle East and Africa. MEA region has experienced. Increased healthcare spending and infrastructure expansion are boosting demand for innovative medical equipment.
Key Market Players
Johnson & Johnson (US), B Braun Medical Inc (Germany), Teleflex Incorporated (US), Medtronic (Ireland), Baxter (US), Medtrade Products Limited (UK), Axio Biosolutions Pvt Ltd (India), MIL Laboratories Pvt. Ltd (India), Becton, Dickinson, and Company (US), and Pfizer Inc (US) are the market's leading players.